Corrigendum to "Discovery of novel taspine derivatives as antiangiogenic agents" [Bioorg. Med. Chem. Lett. 20 (2010) 718] (DOI:10.1016/j.bmcl.2009.11.073);Discovery of novel taspine derivatives as antiangiogenic agents

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 2, 2010, Pages 718-721

  Zhang, Jie ^a   Zhang, Yanmin ^a   Zhang, Sanqi ^a   Wang, Sicen ^a   He, Langchong ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Taspine derivatives; Tyrosine kinase; VEGFR 2 Inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; BIPHENYL; LACTONE; TASPINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; DRUG BINDING SITE; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR DOCKING;

EID: 72549112083     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.026     Document Type: Erratum

References (22)

1. Saaristo A., Karpanen T., and Alitalo L. Oncogene 19 (2000) 6122
2. Gasparrini G., Longo R., Toi M., and Ferrara N. Nat. Clin. Pract. Oncol. 2 (2005) 562
3. Platanova T.F., Kuzovkov A.D., and Sheinker Y.N. J. Gen. Chem. 26 (1956) 2957
4. Bettolo R.M., and Scarpati M.L. Phytochemistry 18 (1979) 520
5. Kennelly E.J., Flynn T.J., Mazzola E.P., Roach J.A., McCloud T.G., Danford D.E., and Betz J.M. J. Nat. Prod. 62 (1999) 1385
6. Li Y.P., and He L.C. Chin. Sci. Bull. 52 (2007) 410
7. Perdue G.P., Blomster R.N., Blake D.A., and Farnsworth N.R. J. Pharm. Sci. 68 (1979) 124
8. Li Y.P., Yang G.D., and He L.C. Zhong Yao Cai 30 (2007) 220
9. Zhang Y.M., He L.C., Meng L., and Luo W.J. Vasc. Pharmacol. 48 (2008) 129
10. Rollinger J.M., Schuster D., Baier E., Ellmerer E.P., Langer T., and Stuppner H. J. Nat. Prod. 69 (2006) 1341
11. Trapani A., Sitterberg J., Bakowsky U., and Kissel T. Int. J. Pharm. 375 (2009) 97
12. 3) δ ppm 1.67 (s, 6H), 3.76 (s, 3H), 3.77 (s, 3H), 3.71 (d, 2H, J = 6.0 Hz), 3.89 (s, 3H), 5.13 (s, 2H), 5.23 (t, J = 6.0 Hz, 1H), 6.79 (s, 1H), 6.89 (d, J = 8.5 Hz, 1H), 7.22-7.33 (m, 5H), 7.39 (s, 1H), 7.69 (s, 1H), 7.79 (d, J = 8.5 Hz, 1 H).
13. Trost B.M., Tang W., and Toste F.D. J. Am. Chem. Soc. 127 (2005) 14785
14. Baret P., Beguin C., Gaude D., Gellon G., Mourral C., Pierre J.L., Serratrice G., and Favier A. Tetrahedron 50 (1994) 2077
15. Burger E.C., and Tunge J.A. Org. Lett. 6 (2004) 4113
16. Kelly T.R., and Xie R.L. J. Org. Chem. 63 (1998) 8045
17. Karamali K., and Mathias G. Tetrahedron 58 (2002) 1159
18. Steâphane Q., Laurent P., Mayalen O., and Matthew A.L. Tetrahedron 57 (2001) 319
19. 3) δ ppm 2.49 (t, J = 7.5 Hz, 2H), 3.52 (t, J = 7.2 Hz, 2H), 3.81 (s, 3H), 3.87 (s, 3 H), 3.95 (s, 3H), 6.88 (d, J = 7.5 Hz, 1H), 6.94 (s, 1H), 6.97-7.10 (m, 2H), 7.19-7.21 (m, 1H), 7.54 (d, J = 9.0 Hz, 1H), 7.68 (s, 1H), 7.77 (s, 1H).
20. Bhal S.K., Kassam K., Peirson I.G., and Pearl G.M. Mol. Pharm. 4 (2007) 556
21. Zhao J., Zhao L., Chen W., He L.C., and Li X. Biomed. Pharmacother. 62 (2008) 383
22. Mou J., Fang H., Jing F., Wang Q., Liu Y., Zhu H., and Xu W. Bioorg. Med. Chem. 17 (2009) 4666